Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

Implications of Immune Checkpoint Expression during Aging for HIV-infected People on ART.

De Armas L, Pallikkuth S, Rinaldi S, Pahwa R, Pahwa S.

AIDS Res Hum Retroviruses. 2019 Oct 3. doi: 10.1089/AID.2019.0135. [Epub ahead of print]

PMID:
31578868
2.

Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.

Amjad F, Bhatti D, Davis TL, Oguh O, Pahwa R, Kukreja P, Zamudio J, Metman LV.

Adv Ther. 2019 Sep;36(9):2233-2246. doi: 10.1007/s12325-019-01014-4. Epub 2019 Jul 5. Review.

PMID:
31278691
3.

Long Term Response to Levodopa in Parkinson's Disease.

Gupta HV, Lyons KE, Wachter N, Pahwa R.

J Parkinsons Dis. 2019;9(3):525-529. doi: 10.3233/JPD-191633.

PMID:
31205007
4.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.

CNS Spectr. 2019 Oct;24(5):574-575. doi: 10.1017/S1092852919000932. No abstract available.

PMID:
31182180
5.

Presumed superficial haemosiderosis presenting with subarachnoid haemorrhage.

Lundin MS, Carter SL, Saeed A, Pahwa R.

BMJ Case Rep. 2019 Jun 8;12(6). pii: e230431. doi: 10.1136/bcr-2019-230431. No abstract available.

PMID:
31177197
6.

Old Drugs, New Delivery Systems in Parkinson's Disease.

Gupta HV, Lyons KE, Pahwa R.

Drugs Aging. 2019 Sep;36(9):807-821. doi: 10.1007/s40266-019-00682-9. Review.

PMID:
31161581
7.

Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.

Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S.

Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 10.1080/17512433.2019.1623669. Epub 2019 Jun 13. Review.

PMID:
31159608
8.

Dysfunctional peripheral T follicular helper cells dominate in people with impaired influenza vaccine responses: Results from the FLORAH study.

Pallikkuth S, de Armas LR, Rinaldi S, George VK, Pan L, Arheart KL, Pahwa R, Pahwa S.

PLoS Biol. 2019 May 17;17(5):e3000257. doi: 10.1371/journal.pbio.3000257. eCollection 2019 May.

9.

Fetuin-A is also an adipokine.

Jialal I, Pahwa R.

Lipids Health Dis. 2019 Mar 27;18(1):73. doi: 10.1186/s12944-019-1021-8.

10.

Extended-Release Amantadine for Levodopa-Induced Dyskinesia.

Dashtipour K, Tafreshi AR, Pahwa R, Lyons KE.

Expert Rev Neurother. 2019 Apr;19(4):293-299. doi: 10.1080/14737175.2019.1592677. Epub 2019 Mar 20.

PMID:
30892103
11.

Single Cell Profiling Reveals PTEN Overexpression in Influenza-Specific B cells in Aging HIV-infected individuals on Anti-retroviral Therapy.

de Armas LR, Pallikkuth S, Pan L, Rinaldi S, Cotugno N, Andrews S, Pahwa R, McDermott AB, Palma P, Pahwa S.

Sci Rep. 2019 Feb 21;9(1):2482. doi: 10.1038/s41598-019-38906-y.

12.

Deep brain stimulation of the subthalamic nucleus in Parkinson's disease patients over 75 years of age.

Sharma VD, Lyons KE, Nazzaro JM, Pahwa R.

J Neurol Sci. 2019 Apr 15;399:57-60. doi: 10.1016/j.jns.2019.02.019. Epub 2019 Feb 11.

PMID:
30772762
13.

An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor.

Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, Dietiker C, Luthra N, Chidester P, Hamner S, Ross E, Delp S.

Neuromodulation. 2019 Jul;22(5):537-545. doi: 10.1111/ner.12930. Epub 2019 Jan 30.

14.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators.

Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Erratum in: Lancet Neurol. 2019 Mar;18(3):e2.

PMID:
30663606
15.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.

CNS Spectr. 2018 Dec;23(6):402-413. doi: 10.1017/S1092852918001359. Review.

PMID:
30588905
16.

The Ties That Bind and Unbound Ties: Experiences of Formerly Homeless Individuals in Recovery From Serious Mental Illness and Substance Use.

Pahwa R, Smith ME, Yuan Y, Padgett D.

Qual Health Res. 2019 Jul;29(9):1313-1323. doi: 10.1177/1049732318814250. Epub 2018 Nov 30.

PMID:
30499369
17.
18.

Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells.

Pallikkuth S, Pahwa R, Kausalya B, Saravanan S, Pan L, Vignesh R, Iqbal S, Solomon SS, Murugavel KG, Poongulali S, Kumarasamy N, Pahwa S.

PLoS One. 2018 Oct 31;13(10):e0206256. doi: 10.1371/journal.pone.0206256. eCollection 2018.

19.

Comparison of the Fahn-Tolosa-Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale.

Ondo W, Hashem V, LeWitt PA, Pahwa R, Shih L, Tarsy D, Zesiewicz T, Elble R.

Mov Disord Clin Pract. 2017 Nov 23;5(1):60-65. doi: 10.1002/mdc3.12560. eCollection 2018 Jan-Feb.

20.

Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.

Pahwa R, Isaacson S, Jimenez-Shaheed J, Malaty IA, Deik A, Johnson R, Patni R.

Parkinsonism Relat Disord. 2019 Mar;60:118-125. doi: 10.1016/j.parkreldis.2018.09.005. Epub 2018 Sep 5.

21.

Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms.

Mitchell KT, Larson P, Starr PA, Okun MS, Wharen RE Jr, Uitti RJ, Guthrie BL, Peichel D, Pahwa R, Walker HC, Foote K, Marshall FJ, Jankovic J, Simpson R, Phibbs F, Neimat JS, Stewart RM, Dashtipour K, Ostrem JL.

Parkinsonism Relat Disord. 2019 Mar;60:126-132. doi: 10.1016/j.parkreldis.2018.09.004. Epub 2018 Sep 6.

PMID:
30220556
22.

Therapeutic Monoclonal Antibodies and the Value of the Free Light Chain Assay in Myeloma.

Jialal I, Pahwa R, Beck RC, Schmotzer CL.

Am J Clin Pathol. 2018 Oct 1;150(5):468-469. doi: 10.1093/ajcp/aqy110. No abstract available.

23.

Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel.

Pahwa R, Isaacson SH, Torres-Russotto D, Nahab FB, Lynch PM, Kotschet KE.

Expert Rev Neurother. 2018 Aug;18(8):669-680. doi: 10.1080/14737175.2018.1503948. Epub 2018 Jul 26.

PMID:
30032695
24.

Atherosclerosis.

Pahwa R, Jialal I.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Apr 17.

25.

Altered immune cell follicular dynamics in HIV infection following influenza vaccination.

Moysi E, Pallikkuth S, De Armas LR, Gonzalez LE, Ambrozak D, George V, Huddleston D, Pahwa R, Koup RA, Petrovas C, Pahwa S.

J Clin Invest. 2018 Jul 2;128(7):3171-3185. doi: 10.1172/JCI99884. Epub 2018 Jun 18.

26.

Psychological Community Integration of Individuals With Serious Mental Illness.

Pahwa R, Kriegel L.

J Nerv Ment Dis. 2018 Jun;206(6):410-416. doi: 10.1097/NMD.0000000000000829.

PMID:
29781895
27.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

28.

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.

Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, Nguyen JT, Patni R, Went GT.

Clin Pharmacokinet. 2019 Jan;58(1):77-88. doi: 10.1007/s40262-018-0663-4.

29.

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.

Sharma VD, Lyons KE, Pahwa R.

Ther Clin Risk Manag. 2018 Apr 12;14:665-673. doi: 10.2147/TCRM.S144481. eCollection 2018. Review.

30.

Pupillary Response to Cognitive Demand in Parkinson's Disease: A Pilot Study.

Kahya M, Moon S, Lyons KE, Pahwa R, Akinwuntan AE, Devos H.

Front Aging Neurosci. 2018 Apr 10;10:90. doi: 10.3389/fnagi.2018.00090. eCollection 2018.

31.

Circulating inflammatory monocytes contribute to impaired influenza vaccine responses in HIV-infected participants.

George VK, Pallikkuth S, Pahwa R, de Armas LR, Rinaldi S, Pan L, Pahwa S.

AIDS. 2018 Jun 19;32(10):1219-1228. doi: 10.1097/QAD.0000000000001821.

PMID:
29683844
32.

Chronic Inflammation.

Pahwa R, Jialal I.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Jun 4.

33.

The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.

Elkurd MT, Bahroo LB, Pahwa R.

Neurodegener Dis Manag. 2018 Apr;8(2):73-80. doi: 10.2217/nmt-2018-0001. Epub 2018 Mar 22. Review.

PMID:
29564954
34.

Gut Microbiome and Inflammation: A Study of Diabetic Inflammasome-Knockout Mice.

Pahwa R, Balderas M, Jialal I, Chen X, Luna RA, Devaraj S.

J Diabetes Res. 2017;2017:6519785. doi: 10.1155/2017/6519785. Epub 2017 Dec 31.

35.

Impact of aging and HIV infection on serologic response to seasonal influenza vaccination.

Pallikkuth S, De Armas LR, Pahwa R, Rinaldi S, George VK, Sanchez CM, Pan L, Dickinson G, Rodriguez A, Fischl M, Alcaide M, Pahwa S.

AIDS. 2018 Jun 1;32(9):1085-1094. doi: 10.1097/QAD.0000000000001774. Erratum in: AIDS. 2019 Mar 15;33(4):771.

36.

Myeloperoxidase Deficiency.

Pahwa R, Jialal I.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Jun 4.

37.

Symptomatic, non-infectious, non-hemorrhagic edema after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease.

Nazzaro JM, Pahwa R, Lyons KE.

J Neurol Sci. 2017 Dec 15;383:42-46. doi: 10.1016/j.jns.2017.10.003. Epub 2017 Oct 12.

PMID:
29246619
38.

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

LeWitt PA, Pahwa R, Sedkov A, Corbin A, Batycky R, Murck H.

J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):155-161. doi: 10.1089/jamp.2016.1354. Epub 2017 Nov 21.

39.

ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia.

Pahwa R, Hauser RA.

JAMA Neurol. 2017 Dec 1;74(12):1507-1508. doi: 10.1001/jamaneurol.2017.3205. No abstract available.

PMID:
29114728
40.

Reevaluation of immune activation in the era of cART and an aging HIV-infected population.

de Armas LR, Pallikkuth S, George V, Rinaldi S, Pahwa R, Arheart KL, Pahwa S.

JCI Insight. 2017 Oct 19;2(20). pii: 95726. doi: 10.1172/jci.insight.95726.

41.

Normal uric acid levels in nascent metabolic syndrome patients residing in northern California.

Jialal I, Pahwa R, Adams-Huet B, Siegel D.

J Diabetes Complications. 2017 Nov;31(11):1639-1640. doi: 10.1016/j.jdiacomp.2017.07.021. Epub 2017 Aug 3. No abstract available.

PMID:
28899611
42.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.

Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.

43.

National randomized controlled trial of virtual house calls for Parkinson disease.

Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W; Connect.Parkinson Investigators.

Neurology. 2017 Sep 12;89(11):1152-1161. doi: 10.1212/WNL.0000000000004357. Epub 2017 Aug 16.

44.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.

Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ.

J Parkinsons Dis. 2017;7(3):511-522. doi: 10.3233/JPD-171134.

45.

Fibroblast Growth Factor 23 Predicts Mortality and End-Stage Renal Disease in a Canadian Asian Population with Chronic Kidney Disease.

Jialal I, Camacho F, Nathoo B, Tam P, Pahwa R, Wu GG.

Nephron. 2017;137(3):190-196. doi: 10.1159/000479300. Epub 2017 Jul 26.

PMID:
28743129
46.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ.

JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943.

47.

Paradoxical aging in HIV: immune senescence of B Cells is most prominent in young age.

Rinaldi S, Pallikkuth S, George VK, de Armas LR, Pahwa R, Sanchez CM, Pallin MF, Pan L, Cotugno N, Dickinson G, Rodriguez A, Fischl M, Alcaide M, Gonzalez L, Palma P, Pahwa S.

Aging (Albany NY). 2017 Apr;9(4):1307-1325. doi: 10.18632/aging.101229.

48.

Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial.

Wharen RE Jr, Okun MS, Guthrie BL, Uitti RJ, Larson P, Foote K, Walker H, Marshall FJ, Schwalb J, Ford B, Jankovic J, Simpson R, Dashtipour K, Phibbs F, Neimat JS, Stewart RM, Peichel D, Pahwa R, Ostrem JL; SJM DBS ET Study Group.

Parkinsonism Relat Disord. 2017 Jul;40:18-26. doi: 10.1016/j.parkreldis.2017.03.017. Epub 2017 Mar 30.

PMID:
28400200
49.

Mental illness disclosure decision making.

Pahwa R, Fulginiti A, Brekke JS, Rice E.

Am J Orthopsychiatry. 2017;87(5):575-584. doi: 10.1037/ort0000250. Epub 2017 Apr 10.

PMID:
28394157
50.

The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome.

Pahwa R, Adams-Huet B, Jialal I.

J Diabetes Complications. 2017 May;31(5):810-813. doi: 10.1016/j.jdiacomp.2017.02.010. Epub 2017 Feb 27.

PMID:
28285929

Supplemental Content

Support Center